114 related articles for article (PubMed ID: 2045313)
1. Continuous infusion of halogenated pyrimidines.
Rodriguez R; Miller E; Fowler JF; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1380-2. PubMed ID: 2045313
[No Abstract] [Full Text] [Related]
2. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo.
Rodriguez R; Ritter MA; Fowler JF; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):105-13. PubMed ID: 8175417
[TBL] [Abstract][Full Text] [Related]
3. Tumour radiosensitization with the halogenated pyrimidines 5'-bromo- and 5'-iododeoxyuridine.
Epstein AH; Cook JA; Goffman T; Glatstein E
BJR Suppl; 1992; 24():209-14. PubMed ID: 1290703
[No Abstract] [Full Text] [Related]
4. Effect of radiation-sensitizing agents in radiation therapy of mouse mammary carcinoma.
Suit HD; Hewitt R; Urano M
Radiology; 1970 Jan; 94(1):189-95. PubMed ID: 5410341
[No Abstract] [Full Text] [Related]
5. Comment on "survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II Study".
Phillips TL
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1281-2. PubMed ID: 8985057
[No Abstract] [Full Text] [Related]
6. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.
Mitchell JB; Russo A; Cook JA; Straus KL; Glatstein E
Int J Radiat Biol; 1989 Nov; 56(5):827-36. PubMed ID: 2573682
[TBL] [Abstract][Full Text] [Related]
7. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study.
Urtasun RC; Kinsella TJ; Farnan N; DelRowe JD; Lester SG; Fulton DS
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1163-7. PubMed ID: 8985039
[TBL] [Abstract][Full Text] [Related]
8. Photon activation therapy (PAT).
Miller RW; DeGraff W; Mitchell JB; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1429. PubMed ID: 3624052
[No Abstract] [Full Text] [Related]
9. Intra-cerebral ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer in the treatment of a rat glioma.
Deutsch M; Rewers AB; Redgate S; Fisher ER; Boggs SS
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):85-7. PubMed ID: 2380099
[TBL] [Abstract][Full Text] [Related]
10. Intraarterial iododeoxyuridine infusion combined with irradiation. A pilot study.
Wirtanen GW; Wiley AL; Vermund H; Stephenson JA; Ansfield FJ
Am J Clin Oncol; 1990 Aug; 13(4):320-3. PubMed ID: 2378311
[TBL] [Abstract][Full Text] [Related]
11. Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine).
Otto SE
J Intraven Nurs; 1998; 21(6):335-7. PubMed ID: 10392098
[TBL] [Abstract][Full Text] [Related]
12. 5-Iodo-2-deoxyuridine administered into the lateral cerebral ventricle as a radiosensitizer in the treatment of disseminated glioma.
Deutsch M; Rewers AB; Redgate ES; Fisher ER; Boggs SS
J Natl Cancer Inst; 1989 Sep; 81(17):1322-5. PubMed ID: 2769785
[TBL] [Abstract][Full Text] [Related]
13. Radiopotentiating action of 1-beta-D-arabinofuranosylcytosine in a xenografted human colonic carcinoma.
Goldenberg DM
Proc Soc Exp Biol Med; 1970 Jun; 134(2):510-2. PubMed ID: 5419139
[No Abstract] [Full Text] [Related]
14. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line.
Kjellström J; Kjellén E; Johnsson A
Acta Oncol; 2005; 44(7):687-93. PubMed ID: 16227158
[TBL] [Abstract][Full Text] [Related]
15. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
[TBL] [Abstract][Full Text] [Related]
16. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure.
Lawrence TS; Davis MA; Maybaum J; Stetson PL; Ensminger WD
Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1393-8. PubMed ID: 2370189
[TBL] [Abstract][Full Text] [Related]
17. Photon activation therapy.
Fairchild RG; Bond VP
Strahlentherapie; 1984 Dec; 160(12):758-63. PubMed ID: 6515666
[TBL] [Abstract][Full Text] [Related]
18. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
[TBL] [Abstract][Full Text] [Related]
19. 5-Iododeoxyuridine increases the efficacy of the radioimmunotherapy of human tumors growing in nude mice.
Santos O; Pant KD; Blank EW; Ceriani RL
J Nucl Med; 1992 Aug; 33(8):1530-4. PubMed ID: 1634946
[TBL] [Abstract][Full Text] [Related]
20. Halogenated pyrimidines as radiosensitizers for high grade glioma: revisited.
Rodriguez R; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):859-62; discussion 865. PubMed ID: 1651310
[No Abstract] [Full Text] [Related]
[Next] [New Search]
